CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 170 enrolled
Drug / intervention
Nivolumab +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02726581
NCT02726581Phase 3Completed
CompareCT.gov

An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Bristol-Myers Squibb·interventional·Posted Apr 1, 2016·Updated Mar 27, 2023

In Brief

A Phase 3 clinical trial evaluating Nivolumab, Elotuzumab, and 2 other interventions for Multiple Myeloma. Completed, enrolled 170 participants across 121 sites in 16 countries.

Detailed Summary

The purpose of this study is to evaluate the safety and effectiveness of several combination therapies for Multiple Myeloma. Upon entry into the study, patients will be randomized (assigned by chance) to receive either: Group 1: nivolumab, pomalidomide and dexamethasone OR Group 2: pomalidomide and dexamethasone OR Group 3: nivolumab, elotuzumab, pomalidomide and dexamethasone. Enrollment is closed for all groups.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesAustria, Canada, Czechia, Denmark, Germany, Greece, Israel, Italy, Norway, Portugal, Puerto Rico, Spain, Sweden, Switzerland, Turkey (Türkiye), United States
CollaboratorsAbbVie

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 1, 2016
Enrollment StartAug 10, 2016
Primary CompletionMar 9, 2022
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 10.3 years ago

Interventions

Nivolumabbiological

Specified dose on specified days, IV (intravenous)

Elotuzumabbiological

Specified dose on specified days, IV

Pomalidomidedrug

Specified dose on specified days, PO (by mouth)

Dexamethasonedrug

Specified dose on specified days, PO